LoQus23 Therapeutics Ltd.. (5/11/22). "Press Release: LoQus23 Therapeutics Ltd. of Cambridge, UK Co-funds New Research Project on Neurological Diseases".

	Region	United Kingdom (GB)
	Organisation	LoQus23 Therapeutics Ltd.
	Organisation 2	National University of Ireland, Galway (NUI Galway)
	Product	preclinical research
	Product 2	research test

Researchers at three universities in Ireland, Scotland and Wales are joining forces to develop new tools for identifying drugs to treat multiple, currently incurable, neurological diseases.

In this new project, the three teams will work together to develop novel technologies to monitor how the number of repeats changes in cells grown in the laboratory. This system will then be used to identify new drugs that slow the rate at which the repeat grows. The hope is that one such drug could then be used to treat multiple inherited disorders, including Huntington’s disease and myotonic dystrophy.

Professor Bob Lahue, at NUI Galway, is leading the research and working with research groups at the University of Glasgow, led by Professor Darren Monckton, and at the UK Dementia Research Institute at Cardiff University, led by Professor Vincent Dion.

The project is titled TRXassay – Development of a novel pre-clinical assay to detect triplet repeat expansions and is co-funded by the European Joint Programme on Rare Diseases (EJP-RD) and by LoQus23 Therapeutics.

https://www.nuigalway.ie/about-us/news-and-events/news-archive/2022/may/nui-galway-leads-new-research-project-on-neurological-diseases

Record changed: 2024-10-05